

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: <http://www.elsevier.com/locate/crvasa>

Guidelines

Summary of the 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Prepared by the Czech Society of Cardiology[☆]



Josef Kautzner^{a,*}, Pavel Osmančík^b, Miloš Táborský^c

^a IKEM, Cardiology, Videnska 1958/9, 140 21 Prague, Czech Republic

^b Department of Medicine III – Cardiology, University Hospital Kralovske Vinohrady and 3rd Medical Faculty of Charles University, Prague, Czech Republic

^c Department of Internal Medicine I – Cardiology, University Hospital Olomouc, 775 20 Olomouc, Czech Republic

Authors of the original ESC guidelines document [1]: Silvia G. Priori, Carina Blomström-Lundqvist on behalf of the ESC Task Force on the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.^{☆☆}

ARTICLE INFO

Article history:

Received 10 January 2016

Accepted 13 January 2016

Available online 23 February 2016

Keywords:

Acute coronary syndrome

Cardiac resynchronization therapy

Cardiomyopathy

Congenital heart disease

Defibrillator

Guidelines

Heart failure

Implantable cardioverter defibrillator

Myocardial infarction

Resuscitation

Stable coronary artery disease

Sudden cardiac death

Tachycardia

Valvular heart disease

Ventricular arrhythmia



EUROPEAN
SOCIETY OF
CARDIOLOGY®



ČESKÁ KARDIOLOGICKÁ SPOLEČNOST
THE CZECH SOCIETY OF CARDIOLOGY

[☆] For permissions: please e-mail: guidelines@escardio.org. ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.

* Corresponding author. Tel.: +420 724208104.

E-mail address: joka@medicon.cz (J. Kautzner).

^{☆☆} Members of this Task Force were selected by the ESC to represent professionals involved with the medical care of patients with this pathology. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk-benefit ratio. Estimates of expected health outcomes for larger populations were included, where data exist.

<http://dx.doi.org/10.1016/j.crvasa.2016.01.009>

0010-8650/© 2016 European Society of Cardiology. All rights reserved. Published by Elsevier Sp.z.o.o. on behalf of the Czech Society of Cardiology.

Contents

1. Preamble	e32
2. Introduction	e32
3. Definitions, epidemiology and future perspectives for the prevention of sudden cardiac death	e32
3.1. Epidemiology of sudden cardiac death	e33
3.1.1. Causes of sudden cardiac death in different age groups	e33
3.2. Autopsy and molecular autopsy in sudden death victims	e33
3.3. Risk prediction of sudden cardiac death	e34
3.3.1. Individuals without known heart disease	e34
3.3.2. Patients with ischaemic heart disease	e34
3.3.3. Patients with inheritable arrhythmogenic diseases	e34
3.4. Prevention of sudden cardiac death in special settings	e34
3.4.1. Screening the general population for the risk of sudden cardiac death	e34
3.4.2. Screening family members of sudden death victims	e34
3.4.3. Screening patients with documented or suspected ventricular arrhythmias	e34
4. Therapies for ventricular arrhythmias	e37
4.1. Treatment of underlying heart disease	e37
4.2. Pharmacotherapy for ventricular arrhythmia and prevention of sudden cardiac death	e38
4.2.1. General management	e38
4.2.2. Anti-arrhythmic drugs	e38
4.2.3. Patients with a cardioverter defibrillator	e41
4.2.4. Electrolytes	e42
4.2.5. Other drug therapy	e42
4.3. Device therapy	e42
4.3.1. Implantable cardioverter defibrillator	e42
4.3.2. Subcutaneous implantable cardioverter defibrillator	e43
4.3.3. Wearable cardioverter defibrillator	e43
4.3.4. Public access defibrillation	e44
4.4. Acute treatment of sustained ventricular arrhythmias	e44
4.5. Interventional therapy	e45
4.5.1. Catheter ablation	e45
4.5.2. Anti-arrhythmic surgery	e46
4.6. Psychosocial impact of implantable cardioverter defibrillator treatment	e46
5. Management of ventricular arrhythmias and prevention of sudden cardiac death in coronary artery disease	e47
5.1. Acute coronary syndromes	e47
5.1.1. Ventricular arrhythmias associated with acute coronary syndromes	e47
5.1.2. Prevention and management of sudden cardiac death associated with acute coronary syndromes: pre-hospital phase	e47
5.1.3. Prevention of sudden cardiac death associated with acute coronary syndromes: in-hospital phase	e47
5.1.4. The prognostic role of early ventricular fibrillation	e51
5.2. Early after myocardial infarction	e51
5.2.1. Risk stratification for sudden cardiac death	e51
5.3. Stable coronary artery disease after myocardial infarction with preserved ejection fraction	e52
5.3.1. Risk stratification	e52
5.3.2. Recommendations for optimal strategy	e52
5.3.3. Use of anti-arrhythmic drugs	e53
5.3.4. Catheter ablation	e53
6. Therapies for patients with left ventricular dysfunction with or without heart failure	e53
6.1. Primary prevention of sudden cardiac death	e53
6.1.1. Drugs	e53
6.1.2. Implantable cardioverter defibrillators	e54
6.1.3. Implantable cardioverter defibrillators in patients with New York Heart Association class IV listed for heart transplantation	e54
6.1.4. Cardiac resynchronization therapy	e54
6.2. Premature ventricular complexes in patients with structural heart disease/left ventricular dysfunction	e55
6.3. Sustained ventricular tachycardia	e56
6.3.1. Drug therapy	e56
6.3.2. Catheter ablation	e56
6.3.3. Implantable cardioverter defibrillator	e57

Download English Version:

<https://daneshyari.com/en/article/2722349>

Download Persian Version:

<https://daneshyari.com/article/2722349>

[Daneshyari.com](https://daneshyari.com)